{‘She possesses zero experience’: the US healthcare establishment prepares for Høeg's appointment at the Food and Drug Administration.

While the United States continues making sweeping adjustments to its vaccine recommendations, an unexpected name has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who first made her name by casting doubt on coronavirus vaccinations in the pandemic and has zeroed in on alleged fatalities following Covid vaccination in her recent time at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Schedule

Health officials had intended to announce major revisions to the pediatric immunization program earlier this month, aligning the US with the Danish immunization schedule, according to reports – a significant shift that would put the US at odds with much of the international standard with little proof for improved outcomes. The planned update has been delayed until the new year.

Instead of Vinay Prasad, Dr. Høeg is listed to address the audience at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

A Shift at the Regulatory Body

This interim role might represent a strengthened alliance between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the agency – and it points to a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing some childhood immunization guidelines in the US to become more similar to Denmark's approach, a society with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccination policy – usually the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of drug regulation.

Doubts Over Expertise

Høeg has little discernible track record in medication creation, oversight or management, which has been standard for past directors of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and CBER since spring.

“It seems she lacks to have any of the qualifications” for running the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past directors of the center would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she lacks the type of experience that previous people who ran the center have had.”

The drug center has an vast range of responsibilities at the agency, the former commissioner stated.

“Many people just pays attention on the novel medication approvals, but the generic program authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and so forth, and all of those need to be managed,” Dr. Woodcock explained. “The area you neglect, that is the part that I always told people is going to bite you.”

There is also, a major administrative component to the position, which supervises over 5,000 employees. “It is a massive administrative position, if you execute it properly,” Woodcock said.

Agency Reaction and Disputed Programs

In response to questions about Høeg’s qualifications and whether this appointment indicates increased cooperation among regulatory chiefs on vaccines, a spokesperson said that the “questions are based on inaccurate presumptions”.

“Her resume aligns with the duties of her role,” the spokesperson explained, pointing to the months Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a controversial expedited therapy clearance system that apparently concerned her predecessors. “How are these medications being selected for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he said, “the agency seems to be moving towards less stringent regulations of most medications, with the exception of shots.”

Public Past Work on Vaccines

Regarding vaccines, Høeg has a more established, if concerning, track record, some experts observe. She authored a study using unverified crowd-sourced reports to estimate the frequency of myocarditis following COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the current administration featured changing regulations for new vaccines and discontinuing “unnecessary” immunizations, she said after the election on a audio program. At the FDA, Høeg has according to sources suggested preventing teenage boys from obtaining Covid vaccines.

“She is an thorough dogmatist who begins with her beliefs and tailors the evidence to retrofit the science in a extremely disingenuous, dishonest fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined fellow dissenters, {like|